These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 2118431

  • 1. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF.
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV, Frank JD, Craft TJ, Sundboom JL, Smith GF.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [Abstract] [Full Text] [Related]

  • 3. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 4. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 5. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1991 May 01; 17(5):738-46. PubMed ID: 1713988
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
    Kopia GA, Kopaciewicz LJ, Fong KL, Crysler CS, Boyle K, Ruffolo RR.
    J Cardiovasc Pharmacol; 1988 Sep 01; 12(3):308-16. PubMed ID: 2464103
    [Abstract] [Full Text] [Related]

  • 7. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep 01; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 8. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul 01; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 9. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov 01; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

  • 10. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K.
    J Cardiovasc Pharmacol; 1991 Jul 01; 18(1):111-9. PubMed ID: 1719279
    [Abstract] [Full Text] [Related]

  • 11. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 01; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 12. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Dec 01; 16(7):1728-35. PubMed ID: 2123910
    [Abstract] [Full Text] [Related]

  • 13. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY, Nichols WW, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1996 Feb 01; 27(2):283-9. PubMed ID: 8720429
    [Abstract] [Full Text] [Related]

  • 14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 15. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, Lucchesi BR.
    Eur J Pharmacol; 1999 Jun 25; 374(3):399-410. PubMed ID: 10422784
    [Abstract] [Full Text] [Related]

  • 16. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 25; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 17. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1993 Dec 25; 22(6):834-40. PubMed ID: 7509901
    [Abstract] [Full Text] [Related]

  • 18. A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
    Saito M, Suzuki S, Yui Y, Kawai C.
    Jpn J Pharmacol; 1994 Sep 25; 66(1):17-23. PubMed ID: 7532243
    [Abstract] [Full Text] [Related]

  • 19. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb 25; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 20. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Sep 25; 63(1):9-16. PubMed ID: 8271535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.